Trial Profile
An Open-Label, Randomized, Multicenter Phase III Study in Patients With HER2-Positive Metastatic Breast Cancer Responding to First Line Treatment With Intravenous Trastuzumab for at Least 3 Years and Investigating Patient Preference for Subcutaneous Trastuzumab
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Trastuzumab (Primary) ; Trastuzumab
- Indications Advanced breast cancer; Male breast cancer
- Focus Registrational; Therapeutic Use
- Acronyms Metaspher
- Sponsors Roche
- 11 Sep 2019 Status changed from active, no longer recruiting to completed.
- 01 Sep 2017 Primary endpoint (Percentage of Participants With Preference for Either SC or IV Route of Administration According to Participant Preference Questionnaire (PPQ) Score) has been met, according to the results published in the European Journal of Cancer
- 01 Sep 2017 Results published in the European Journal of Cancer